Literature DB >> 10577720

A field trial of the effectiveness of a feline Toxoplasma gondii vaccine in reducing T. gondii exposure for swine.

N E Mateus-Pinilla1, J P Dubey, L Choromanski, R M Weigel.   

Abstract

A 3-yr field trial was conducted on 8 commercial swine farms in Illinois to determine the effectiveness of a feline Toxoplasma gondii vaccine in reducing the exposure of swine to T. gondii. A vaccine consisting of live bradyzoites of the mutant T-263 strain, capable of preventing oocyst shedding by cats, was used in this study. Each farm was visited 3 times in 1994, 3 times in 1995, and once in 1996. Cats were trapped and inoculated with the T-263 oral vaccine during 1994 and 1995. On each visit, the following samples were collected: blood from pigs, cats, and mice for detection of serum antibodies to T. gondii, feces from cats to detect oocysts, and heart and brain tissues from rodents to determine the presence of T. gondii tissue cysts. The modified agglutination test (MAT), with a positive titer set at the 1:25 dilution, was used to determine serum antibodies. At first capture, 72.6% (61/84) of juvenile cats and 32.6% (31/95) of adult cats had no detectable antibodies (seronegative), indicating no prior exposure to T. gondii when they received their first vaccine. Of these first-time seronegative cats, 58.1% (18/31) of adult and 45.9% (28/61) of juvenile cats were recaptured and received a second dose of vaccine. Changes in the prevalence of T. gondii infection were evaluated from the prevaccination (1992, 1993) to the postvaccination (1996) period. Eleven cats (5%) were detected shedding oocysts between 1994 and 1996, of which 10 (90.1%) shed during 1994. The last detection of oocyst shedding by cats was during the first farm visit in 1995. There was a significant decrease in T. gondii seroprevalence for finishing pigs (P < 0.05, Wilcoxon sign rank test). There was a positive correlation (Spearman's p = 1.0, P < 0.0001) between the change in prevalence in juvenile cats and the change in prevalence in finishing pigs. The seropositivity rate (MAT > or = 1:25) in mice among all farms decreased from 4% in 1992-1993 to 0% in 1996. The mean prevalence of T. gondii tissue cyst isolation for mice on all farms decreased from 1.1% in 1994, to 0.8% in 1995, and to 0.5% in 1996. The results of this study suggest that the reduced exposure of pigs to T. gondii was due to the administration of the T. gondii vaccine to cats.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10577720

Source DB:  PubMed          Journal:  J Parasitol        ISSN: 0022-3395            Impact factor:   1.276


  16 in total

1.  A comparative analysis of coprologic diagnostic methods for detection of Toxoplama gondii in cats.

Authors:  Harold Salant; Dan T Spira; Joseph Hamburger
Journal:  Am J Trop Med Hyg       Date:  2010-05       Impact factor: 2.345

2.  Increased Toxoplasma gondii positivity relative to age in 125 Scottish sheep flocks; evidence of frequent acquired infection.

Authors:  Frank Katzer; Franz Brülisauer; Esther Collantes-Fernández; Paul M Bartley; Alison Burrells; George Gunn; Stephen W Maley; Chris Cousens; Elisabeth A Innes
Journal:  Vet Res       Date:  2011-12-21       Impact factor: 3.683

3.  Protective efficacy of a Toxoplasma gondii rhoptry protein 13 plasmid DNA vaccine in mice.

Authors:  Pei-Yuan Wang; Zi-Guo Yuan; Eskild Petersen; Jie Li; Xiu-Xiang Zhang; Xiu-Zhen Li; Hao-Xin Li; Zhi-Cheng Lv; Tian Cheng; Di Ren; Gui-Lian Yang; Rui-Qing Lin; Xing-Quan Zhu
Journal:  Clin Vaccine Immunol       Date:  2012-09-26

Review 4.  Challenges in Veterinary Vaccine Development.

Authors:  Sunil Thomas; Ann Abraham; Alina Rodríguez-Mallon; Sasimanas Unajak; John P Bannantine
Journal:  Methods Mol Biol       Date:  2022

5.  Self-mating in the definitive host potentiates clonal outbreaks of the apicomplexan parasites Sarcocystis neurona and Toxoplasma gondii.

Authors:  Jered M Wendte; Melissa A Miller; Dyanna M Lambourn; Spencer L Magargal; David A Jessup; Michael E Grigg
Journal:  PLoS Genet       Date:  2010-12-23       Impact factor: 5.917

6.  The transcriptome of Toxoplasma gondii.

Authors:  Jay R Radke; Michael S Behnke; Aaron J Mackey; Josh B Radke; David S Roos; Michael W White
Journal:  BMC Biol       Date:  2005-12-02       Impact factor: 7.431

7.  An experimental Toxoplasma gondii dose response challenge model to study therapeutic or vaccine efficacy in cats.

Authors:  Jan B W J Cornelissen; Joke W B van der Giessen; Katsuhisa Takumi; Peter F M Teunis; Henk J Wisselink
Journal:  PLoS One       Date:  2014-09-03       Impact factor: 3.240

8.  Immuno-Efficacy of a T. gondii Secreted Protein with an Altered Thrombospondin Repeat (TgSPATR) As a Novel DNA Vaccine Candidate against Acute Toxoplasmosis in BALB/c Mice.

Authors:  Bin Zheng; Jianzu Ding; Xiaoheng Chen; Haijie Yu; Di Lou; Qunbo Tong; Qingming Kong; Shaohong Lu
Journal:  Front Microbiol       Date:  2017-02-17       Impact factor: 5.640

Review 9.  Successful vaccines for naturally occurring protozoal diseases of animals should guide human vaccine research. A review of protozoal vaccines and their designs.

Authors:  Milton M McAllister
Journal:  Parasitology       Date:  2014-01-28       Impact factor: 3.234

Review 10.  Use of Veterinary Vaccines for Livestock as a Strategy to Control Foodborne Parasitic Diseases.

Authors:  Valeria A Sander; Edwin F Sánchez López; Luisa Mendoza Morales; Victor A Ramos Duarte; Mariana G Corigliano; Marina Clemente
Journal:  Front Cell Infect Microbiol       Date:  2020-06-26       Impact factor: 5.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.